These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35898435)

  • 1. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
    Snow A; Zeidner JF
    Ther Adv Hematol; 2022; 13():20406207221112899. PubMed ID: 35898435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
    Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
    J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
    Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
    Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
    Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
    Handa H; Cheong JW; Onishi Y; Iida H; Kobayashi Y; Kim HJ; Chiou TJ; Izutsu K; Tsukurov O; Zhou X; Faessel H; Yuan Y; Sedarati F; Faller DV; Kimura A; Wu SJ
    J Hematol Oncol; 2022 May; 15(1):56. PubMed ID: 35545778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia.
    Guo N; Azadniv M; Coppage M; Nemer M; Mendler J; Becker M; Liesveld J
    Transl Oncol; 2019 Apr; 12(4):602-613. PubMed ID: 30699367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
    Pophali P; Desai SR; Shastri A
    Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
    Tarlock K; Liu X; Minard CG; Isikwei EA; Reid JM; Horton TM; Fox E; Weigel BJ; Cooper T
    Pediatr Blood Cancer; 2023 Dec; 70(12):e30672. PubMed ID: 37710306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Du Y; Li C; Zhao Z; Liu Y; Zhang C; Yan J
    BMC Cancer; 2023 Aug; 23(1):764. PubMed ID: 37592239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.
    Yang X; Ma L; Zhang X; Huang L; Wei J
    Exp Hematol Oncol; 2022 Mar; 11(1):11. PubMed ID: 35236415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
    Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
    Ishikawa Y; Nakayama K; Morimoto M; Mizutani A; Nakayama A; Toyoshima K; Hayashi A; Takagi S; Dairiki R; Miyashita H; Matsumoto S; Gamo K; Nomura T; Nakamura K
    Oncogenesis; 2017 Sep; 6(9):e377. PubMed ID: 28892104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    El-Cheikh J; Bidaoui G; Saleh M; Moukalled N; Abou Dalle I; Bazarbachi A
    Clin Hematol Int; 2023 Jun; 5(2-3):143-154. PubMed ID: 37071328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Wong KK; Hassan R; Yaacob NS
    Front Oncol; 2021; 11():624742. PubMed ID: 33718188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
    Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
    Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Hypomethylating Agents for Better MDS Therapy.
    Bradley TJ; Watts JM; Swords RT
    Curr Hematol Malig Rep; 2018 Dec; 13(6):507-515. PubMed ID: 30267380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.